אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; iron oxide yellow - as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephritic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. patients with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol / l) serum cholesterol levels. patients with unstable angina pectoris. as an adjunct to diet and lifestyle modification for the treatment of heterozygenous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; iron oxide red; croscarmellose sodium; lactose monohydrate - as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephritic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. patients with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol / l) serum cholesterol levels. patients with unstable angina pectoris. as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older.

קנדה - אנגלית - Health Canada

sivem pharmaceuticals ulc - pravastatin sodium - tablet - 10mg - pravastatin sodium 10mg - hmg-coa reductase inhibitors

קנדה - אנגלית - Health Canada

sivem pharmaceuticals ulc - pravastatin sodium - tablet - 20mg - pravastatin sodium 20mg - hmg-coa reductase inhibitors

קנדה - אנגלית - Health Canada

sivem pharmaceuticals ulc - pravastatin sodium - tablet - 40mg - pravastatin sodium 40mg - hmg-coa reductase inhibitors

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; iron oxide yellow; magnesium oxide; croscarmellose sodium; microcrystalline cellulose; povidone; lactose monohydrate - as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction and average (normal) serum cholesterol levels (see clinical trials). indications as at 23 january 2004: as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. pravachol is indicated in patients with unstable angina pectoris (see clinical trials). pravachol is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trails).

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; magnesium stearate; povidone; microcrystalline cellulose; lactose monohydrate; iron oxide yellow; magnesium oxide - as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction and average (normal) serum cholesterol levels (see clinical trials). indications as at 23 january 2004: as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. pravachol is indicated in patients with unstable angina pectoris (see clinical trials). pravachol is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trails).

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 40 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; magnesium oxide; magnesium stearate; povidone; lactose monohydrate; iron oxide yellow; microcrystalline cellulose - as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg, poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysprotenemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. indications as at 20 august 1996: as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia, (e.g. poorly controlled diabetes mellitus, hypothroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. indications as at 2 march 1999: as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction and average (normal) serum cholesterol levels (see clinical trials). indications as at 4 august 1999: as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction and average (normal) serum cholesterol levels (see clinical trials). pravachol is indicated in patients with unstable angina pectoris (see clinical trials). indications as at 23 january 2004: as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. pravachol is indicated in patients with unstable angina pectoris (see clinical trials). pravachol is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trails).

אירלנד - אנגלית - HPRA (Health Products Regulatory Authority)

norton waterford - pravastatin sodium - tablet - 10 milligram(s) - hmg coa reductase inhibitors; pravastatin

אירלנד - אנגלית - HPRA (Health Products Regulatory Authority)

norton waterford - pravastatin sodium - tablet - 20 milligram(s) - hmg coa reductase inhibitors; pravastatin